MPN Cancer Connection

03/24/2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and...

03/20/2026

Abstract: Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis

Ruxolitinib and subsequent JAK2 inhibitors have improved care for some patients with the myeloproliferative neoplasms myelofibrosis, essential thrombocythe

03/19/2026

MPN Financial Assistance Programs are Available

New research shows a big gap in MPN care: even with recent Medicare changes, 40% of patients still struggle to afford their medications.

Whether you’re living with PV, ET, or Myelofibrosis, knowing where to find financial help is more important than ever. Read our latest article to find resources that can help you or your loved ones handle these costs. 🩺

https://mpncancerconnection.org/2026/03/mpn-financial-assistance-research-reveals-growing-need/

03/15/2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib

Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and inste...

03/11/2026

Partner Corner: PV In Focus:

Join us for a day of community and education on polycythemia vera!

📍 New York, NY - April 18
Birmingham, AL - April 25

Topics include:
- PV overview and treatment options
- A patient's perspective
- Self-advocacy
- Mental health
Breakfast and lunch provided.
More details/Register—https://PVinFocus.com

03/06/2026

Patient Engagement Predicts Self-Care Behaviors in Patients With Myeloproliferative Neoplasms

In reflecting on the findings, the investigators highlighted that “self-efficacy fully mediated the relationship between engagement and self-care.”

02/27/2026

New Research: A Clue to Anemia in SRSF2-Mutant MPN Patients

A study just published in Leukemia may explain why patients with both JAK2 and SRSF2 mutations often have lower red blood cell counts. The SRSF2 mutation causes a cellular pathway to get "stuck in overdrive," blocking the bone marrow from making red blood cells properly.

The promising finding: rapamycin, an already-approved drug, restored normal red blood cell production in lab and patient samples by shutting down that overactive pathway.
Still early-stage research, but a real step toward treating anemia in this patient subset.

Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of SRSF2 mutations on erythropoiesis. We found reduced erythropoiesis in Srsf2P95H...

02/04/2026

Today is World Cancer Day 2026. 👇

Since 2013, we've been dedicated to helping MPN cancer patients live better lives. MPN Cancer Connection and PV Reporter provide the tools you need to become your own advocate, connect with MPN specialists, and access educational programs on emerging treatment options.

Led by founder David Wallace and our dedicated team, we bring a unique patient perspective to the MPN community, translating complex research into actionable information you can use.

01/24/2026

Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis

Investigators are currently evaluating zavabresib plus ruxolitinib among patients with myelofibrosis in the phase 1 PROMise study.

01/19/2026

Posted for PV Patient in NYC:

Do you need support?
Are you looking for an MPN community?

IN PERSON
New York City Support Group Forming

I am a PV patient who lives in Manhattan.

I am hoping that, like me, you are looking to connect, IN PERSON. Zoom is just not the same! Nothing beats personal face to face connection.

We can meet to share information, assist with research, help with hospital or doctors’ appointments or hospital visits, or offer emotional and psychological support. We can create a strong community. And, if you don’t have family nearby to reach out to, having a community to call on becomes even more psychologically critical.

Please consider joining me to create the kind of care giving we all need as we deal with chronic disease.

I hope you are interested!

Shelley
Eyewoman@aol.com

Please let me know where you are located and how you can best be reached.

Thank you!

01/08/2026

FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis

/PRNewswire/ -- Cellenkos® Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf, regulatory T cell (Treg) therapies for autoimmune...

01/06/2026

Big News for the Myelofibrosis Community! 📣

For a long time, many Myelofibrosis patients in the early stages have been told to "watch and wait." But a new 2025 study suggests that "acting early" might be the better path.

The study found that using Interferon early on can help reduce bone marrow scarring and lower the "burden" of the disease. This is a huge win for those looking for proactive ways to manage their health!

Check out the article to learn more about these findings: 👉

Early interferon treatment in pre-fibrotic myelofibrosis may slow disease progression, reduce fibrosis, and challenge the long-standing watch-and-wait approach.